Immix biopharma, inc. (IMMX) 2025Q3 financial report shows operating expenses of 7.66M USD, roughly flat compared to last year, reflecting a stable operating structure, possibly due to cost optimization or successful product strategies. It is recommended to also monitor revenue, gross margin, and expense structure, and compare with peers. Integrating diversified data and Growin AI Value Analysis, such stable spending usually suggests the company has entered a more mature management stage, with balanced internal efficiency and resource allocation.